CRC Research Update — October 30, 2026
Today's colorectal cancer research highlights
kras
A collection of 116 issues
PIK3C3 inhibition enhances 5-FU sensitivity in KRAS-mutant cells, opposite effect in KRAS-wild-type
Skip to content
The CRC Digest
◇ RESEARCH
PIK3C3 inhibition enhances 5-FU sensitivity in KRAS-mutant cells, opposite effect in KRAS-wild-type
Laboratory study found PIK3C3 knockdown increased 5-fluorouracil resistance in KRAS-wild-type cells but enhanced sensitivity in KRAS-mutant cells, potentially through thymidylate synthase regulation. (Cancer Medicine)
This content is informational only and does
CRC Research Update — October 29, 2026
Today's colorectal cancer research highlights
Pharmacokinetic method developed for pan-RAS inhibitor
Skip to content
The CRC Digest
▸ TREATMENT
Pharmacokinetic method developed for pan-RAS inhibitor
Researchers validated a mass spectrometry assay to measure daraxonrasib, an oral pan-RAS inhibitor in clinical evaluation for colorectal cancer, in canine plasma and whole blood, supporting pharmacokinetic characterization of the investigational drug. (Biomed Chromatogr)
This content is
CRC Research Update — October 25, 2026
Today's colorectal cancer research highlights
Molecular profiling study identifies clinicopathological factors linked to dMMR/MSI-H status
Skip to content
The CRC Digest
Molecular profiling study identifies clinicopathological factors linked to dMMR/MSI-H status
In 272 resected colorectal cancers, dMMR/MSI-H was present in 9.6% of tumors and independently associated with younger age, proximal tumor location, and poor differentiation. (Clinical Therapeutics)
This content is informational only
Large cohort study maps RAS-pathway mutation patterns in 1,243 colorectal cancer samples
Skip to content
The CRC Digest
◇ RESEARCH
Large cohort study maps RAS-pathway mutation patterns in 1,243 colorectal cancer samples
Whole-exome sequencing revealed KRAS mutations in 35.3% of tumors, BRAF V600E in 6.8%, and PIK3CA in 17.8%, with KRAS-PIK3CA co-mutations occurring in 10.1% overall; RAS-mutant tumors
CRC Research Update — October 24, 2026
Today's colorectal cancer research highlights
CRC Research Update — October 23, 2026
Today's colorectal cancer research highlights
KRAS, NRAS, and BRAF mutation frequencies reported in Iranian metastatic CRC cohort
Skip to content
The CRC Digest
KRAS, NRAS, and BRAF mutation frequencies reported in Iranian metastatic CRC cohort
Among 83 patients with metastatic colorectal cancer, mutation frequencies were 47% for KRAS, 14.5% for NRAS, and 6% for BRAF; BRAF mutations were significantly more frequent in patients under 50 years